A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
Feature|Articles|June 27, 2025
Biden’s prostate cancer diagnosis underscores importance of screening, awareness
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
Advertisement
Advertisement
Former President Joseph R. Biden’s recent diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has offered a sobering reminder that prostate cancer remains a growing concern for public health. In the US, incidence rates have been steadily rising since 2014, driven primarily by increases in advanced disease. The American Cancer Society (ACS) estimates that in 2025, more than 313,000 men will be diagnosed with prostate cancer and over 35,000 men will die from the disease.1
Related to this article
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.
Advertisement
Advertisement